PTC Therapeutics (PTCT) Provides Regulatory Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
PTC Therapeutics Provides Key Regulatory Updates
March 19, 2024 7:30 AM UTC-Â BLA submitted to FDA for Upstaza for the treatment of AADC deficiency -
-Â NDA to be submitted mid-year for Translarna based on FDA feedback -
SOUTHÂ PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ --Â PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza (eladocagene exuparvovec), a gene therapy for the treatment of... More
